Child Health
Our familial short stature guide and constitutional growth delay guide cover the two most familiar reasons a healthy child is short, and our growth hormone therapy guide covers treatment. This piece explains the diagnosis many families hear after a normal growth workup: idiopathic short stature. It covers what the label means and doesn't mean, how doctors reach it, what genetic testing is now finding, and the full range of options, including the one most families end up choosing: careful monitoring.
What Doctors Find When a Healthy Child Is Short
Diagnoses in asymptomatic short children, and how often genetic testing finds a cause in ISS
What "Idiopathic Short Stature" Actually Means
ISS isn't found by a single test. It's what remains when a child is clearly short but history, exam, bloodwork, and growth hormone testing don't point to any disease.
Most children with ISS are growing at a normal rate along a low curve. The label describes their height, not an illness, and many simply have a smaller build than average.
A 2008 international consensus statement from the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology defined ISS as height below -2 SDS without evidence of disease after a complete evaluation by a pediatric endocrinologist, including stimulated growth hormone levels. Clinics don't always use the term the same way. Some count familial short stature and constitutional delay as subtypes of ISS, while others, like the Cincinnati review in the chart above, list them separately and reserve ISS for children who fit neither pattern.
How Doctors Reach the Diagnosis
The evaluation is about ruling things out in a sensible order rather than running every possible test. Growth pattern over time is the most important piece of information a family can bring.
Height over time, growth rate, and both parents' heights
Looking for features of a syndrome or skeletal condition
Bloodwork, bone age, and GH testing as indicated
The child is classified as ISS and followed over time
That cost figure is part of why pediatric endocrinologists have rethought routine screening. The American Academy of Pediatrics Section on Endocrinology, through the Choosing Wisely campaign, advises against nondirected laboratory screening in short children who are otherwise healthy, noting that new pathology turned up in only about 1% of such children. It suggests that a tiered or step-by-step approach may be considered for children who are significantly short, around -2.5 SDS or below, or well below their expected height based on their parents. A child whose growth rate is slowing is a different situation and needs prompt evaluation; our growth velocity guide explains how to tell the difference.
Genetics Is Shrinking the "Idiopathic" Group
Height is strongly heritable, as our guide to how much of height is genetic explains, and much of ISS likely reflects normal genetic variation. But some children labeled ISS turn out to carry a single gene change with a larger effect.
In a 2022 study published in Endocrine Connections, researchers in Brazil tested 102 children with ISS using a panel of genes already linked to isolated short stature. They found pathogenic or likely pathogenic variants in 17 children, a yield of 16.7%, or about 1 in 6. Most involved genes that control growth plate development, such as IHH, SHOX, FGFR3, NPR2, and ACAN, and a smaller number involved a cell-signaling pathway linked to conditions like Noonan syndrome. The yield was much higher in children with severe short stature (35%) than in those less severely short (12.2%), and the genetic result changed clinical management for four children. A finding like this can explain why a child is short, guide genetic counseling for the family, and in some conditions affect treatment decisions.
Genetic testing isn't routine for every short child yet. Panels differ in which genes they include, results can be uncertain, and most children with ISS still won't receive a genetic explanation. Testing is more likely to be offered when short stature is severe, when a parent is also very short, or when there are subtle features such as unusual body proportions. The Brazilian authors expect testing to become a routine part of the workup as costs fall and diagnostic yield rises, but for now it's a conversation to have with a pediatric endocrinologist rather than a standard first step.
Options After an ISS Diagnosis
There's no single right path. The 2008 consensus and the 2016 Pediatric Endocrine Society guidelines both frame management as a decision made with the family, based on how short the child is, how the child feels about it, and the trade-offs of each option.
The 2016 guidelines advise against routinely treating ISS with growth hormone and call for a reassessment of height gain and psychosocial impact after 12 months if treatment is started. The consensus also cautioned that predicted adult height can be inaccurate and shouldn't be the sole basis for deciding to treat.
What research says about height and social life. A common reason families consider treatment is worry that being short will hurt a child socially. In a 2004 Pediatrics study of 956 students in grades 6 through 12, peer ratings showed that height was unrelated to how well students were liked, their reputation among classmates, or their friendships. The researchers cautioned against attributing social problems to height alone and suggested looking for other contributing factors. Individual experiences vary, and teasing is real for some children, which is why the consensus emphasizes psychological support as an option in its own right.
What This Means For You
The practical takeaway: idiopathic short stature means a child is clearly short but a careful evaluation hasn't found a reason, and for most families that's reassuring news. Genetic testing now finds an explanation for about 1 in 6 children with ISS, more often when shortness is severe. Treatment options exist, including growth hormone, but the gains are modest and guidelines favor a shared decision, with monitoring and emotional support as equally valid paths. To compare ISS with the two most common normal variants, see our familial short stature guide and constitutional growth delay guide, and if growth seems to be slowing, see our guide on when to worry about a child's height.
Frequently Asked Questions
What is idiopathic short stature?
It describes a child whose height is below -2 SDS for age and sex, roughly the shortest 2.3%, with no cause found after a complete evaluation by a pediatric endocrinologist, including growth hormone testing. "Idiopathic" means the cause is unknown. Most children with ISS are healthy and growing at a normal rate along a low curve.
Is idiopathic short stature a disease?
Not in itself. It's a description of height after other causes have been ruled out. In a U.S. review of 235 otherwise healthy short children, about 99% had normal variants of growth. Some children with ISS do turn out to have a genetic cause when tested, which is why the label can change over time.
Can genetic testing explain idiopathic short stature?
Sometimes. A 2022 study that tested 102 children with ISS using a gene panel found a likely genetic cause in 16.7%, about 1 in 6, and in 35% of children who were most severely short. Common findings involved genes that control growth plate development, such as SHOX, ACAN, and NPR2.
Should a child with ISS get growth hormone?
It's an individual decision. Growth hormone is FDA-approved for ISS, but the average adult height gain is about 3.5 to 7.5 cm after 4 to 7 years of treatment, and not every child responds. The 2016 Pediatric Endocrine Society guidelines advise against routine treatment and recommend a shared decision with a 12-month reassessment if treatment begins.
Will a child with idiopathic short stature be short as an adult?
Many will remain on the shorter side, especially if their parents are short, but height outcomes vary. Children whose short stature reflects a delayed growth pattern may catch up later, which is one reason doctors follow growth over time rather than relying on a single prediction.
